**Composition**
Olopatadine hydrochloride 0.2% (2 mg/mL)

**Action**
Olopatadine is an inhibitor of the release of histamine from the mast cell and a relatively selective histamine H1-antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.

**Indications**
Allnex-S is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

**Contraindications**
Contraindicated in persons with a known hypersensitivity to olopatadine hydrochloride or any components.

**Warnings**
Not for injection
Allnex-S for topical use only and not for injection or oral use.

**Adverse Reactions**
Symptoms similar to cold syndrome and pharyngitis were reported at an incidence of approximately 10%.
The following adverse experiences have been reported in 5% or less of patients:
*Ocular:* blurred vision, burning or stinging, conjunctivitis, dry eye, foreign body sensation, hyperemia, hypersensitivity, keratitis, lid edema, pain and ocular pruritus.
*Non-ocular:* asthenia, back pain, flu syndrome, headache, increased cough, infection, nausea, rhinitis, sinusitis and taste perversion.

**Post Marketing Experience**
The following adverse reactions have been reported during clinical studies with Olopatadine solution 0.2% Eye Drops and are classified according to the subsequent convention: very common (≥ 1/10), common (≥ 1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000) and very rare (<1/10,000). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.

**Eye disorders**
Uncommon (≥ 0.1% to < 1%): punctate keratitis, keratitis, eye pain, dry eye, eyelid oedema, eye pruritus, eye discharge, ocular hyperaemia, eyelid margin crusting, ocular discomfort
Rare (≥ 0.01% to < 0.1%): photophobia, vision blurred, erythema of eyelid

**Nervous system disorders**
Uncommon (≥ 0.1% to < 1%): headache, dysgeusia
Rare (≥ 0.01% to < 0.1%): dizziness

**Respiratory, thoracic and mediastinal disorders**
Uncommon (≥ 0.1% to < 1%): nasal dryness

**Gastrointestinal disorders**:
Rare (≥ 0.01% to < 0.1%): dry mouth

**Skin and subcutaneous tissue disorders**:
Rare (≥ 0.01% to < 0.1%): dermatitis contact

**General disorders and administration site conditions:**
Uncommon (≥ 0.1% to < 1%): fatigue
Additional adverse reactions identified from post-marketing surveillance include the following. Frequencies cannot be estimated from the available data.

**Eye disorders**
Lacrimation increased

**Immune system disorders**
Hypersensitivity

**Gastrointestinal disorders**
Nausea

**Precautions**
**Wearing of contact lenses:** patients whose eyes are red should not wear contact lenses at all. Patients whose eyes are not red should wait 15 minutes after instilling the drops before inserting soft contact lenses

**Pregnancy**
*Category C*
Olopatadine was found not to be teratogenic in rats and rabbits. However, rats treated at 600 mg/kg/day, or 93,750 times the MROHD and rabbits treated at 400 mg/kg/day, or 62,500 times the MROHD, during organogenesis showed a decrease in live fetuses. There are, however, no adequate and well controlled studies in pregnant women. Because animal studies are not always predictive of human responses, this drug should be used in pregnant women only if the potential benefit to the mother justifies the potential risk to the embryo or fetus.

**Nursing Mothers**
Olopatadine has been identified in the milk of nursing rats following oral administration. It is not known whether topical ocular administration could result in sufficient systemic absorption to produce detectable quantities in the human breast milk. Nevertheless, caution should be exercised when olopatadine hydrochloride ophthalmic solution 0.1% is administered to a nursing mother.

**Pediatric Use**
Safety and effectiveness in pediatric patients below the age of 3 years have not been established.

**Geriatric Use**
No overall differences in safety or effectiveness have been observed between elderly and younger patients.

**Drug Interactions**
No information provided.

**Dosage and Administration**
The recommended dose is one drop in each affected eye once a day.

To prevent contamination of the dropper tip and solution, care must be taken not to touch the eyelids, surrounding areas, or other surfaces with the dropper tip of the bottle. Keep the bottle tightly closed when not in use.

In case of concomitant therapy with other topical ocular medicines, an interval of five to ten minutes should be allowed between successive applications.
Presentation
Dropper bottle of 2.5 ml